Navigation Links
Echo Therapeutics Announces First Quarter 2012 Financial Results

PHILADELPHIA, May 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the quarter ended March 31, 2012.  Echo's Quarterly Report on Form 10-Q as filed with the SEC is available through Echo's website at

Recent Corporate Highlights

  • Echo initiated clinical studies of its Symphony tCGM System in critically ill patients in two hospitals.  The company announced positive results from its clinical study conducted at Tufts Medical Center in Boston, Massachusetts.  Data from that study demonstrated that Symphony reliably monitored glucose levels in an intensive care unit.  Results from the second study are expected in the second quarter.
  • Echo announced the issuance of multiple patents that provide its products with long-term market protection.  Echo has obtained 6 U.S. patents and 65 foreign patents, and has 35 U.S. and foreign patent applications pending.
  • "We continue to advance the significant clinical and product development progress we made during 2011, including our recent announcement of positive results from our Symphony trial in critically ill patients at Tufts Medical Center.  We are highly encouraged by the success of the trial and believe Symphony offers a potential to advance the standard of care regarding glycemic control in the hospital critical care setting," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "With several important milestones still ahead, we look forward to increased shareholder value and bringing Symphony closer to commercialization."

    First Quarter 2012 Financial ResultsEcho's net loss for the first quarter of 2012 was $3.0 million, or ($0.08) per share, compared to $6.6 million, or ($0.20) per share, for the first quarter of 2011.  Operating loss for the first quarter of 2012 was $3.2 million compared to $1.6 million for the first quarter of 2011.  Research and development expenses were $1.4 million for the first quarter of 2012 compared to $0.9 million in the prior year.  The increase in research and development expenses are primarily related to increased manufacturing, development and clinical expenses, as well as personnel costs.  General and administration expenses were $1.9 million for the first quarter of 2012 versus $0.9 million in the prior year.  The increase in general and administrative expenses was primarily due to increased personnel and facility costs, as well as legal and other Nasdaq and public company expenses. The Company reported a cash balance of approximately $5.9 million as of March 31, 2012.Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104

    Connect With Us:
    - Visit our website at 
    - Follow us on Twitter at 
    - Join us on Facebook at Echo Therapeutics, Inc.Condensed Consolidated Balance Sheets   March 31,2012December 31,2011ASSETSCurrent Assets:Cash and cash equivalents

    8,995,571Cash restricted pursuant to vendor letter of credit

    250,000250,000Other current assets

    317,624317,940Total current assets

    6,477,8379,563,511Net property and equipment (including assets under capitalized leases

    370,549317,731Intangible assets, net of accumulated amortization

    9,625,0009,625,000Restricted cash, deposits and other assets

    10,81620,565Total assets

    9,526,807LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    365,298Deferred revenue

    123,708123,708Derivative warrant liability

    803,7941,035,337Accrued expenses and other liabilities

    389,059968,120Total current liabilities

    1,953,2192,492,463Deferred revenue, notes payable and capital lease obligation, net of current portion and discounts

    34,22065,755Total liabilities

    1,987,4392,558,218CommitmentsStockholders' Equity:Convertible preferred stock, Series C & D

    30,16030,160Common stock

    388,363385,442Additional paid-in capital

    98,634,01798,116,327Common stock subscribed for but not paid for or issued

    -6,667Accumulated deficit

    (84,555,777)(81,570,007)Total stockholders' equity

    14,496,76316,968,589Total liabilities and stockholders' equity

    9,526,807Condensed Consolidated Statements of OperationsThree Months Ended March 31,20122011Licensing revenue

    21,455Other revenue

    -108,087Total revenues

    30,927229,542Operating Expenses:Research and development

    1,391,645865,950Selling, general and administrative

    1,859,404918,750Total operating expenses

    3,251,0491,784,700Loss from operations

    (3,220,122)(1,555,158)Other Income (Expense):Interest income (expense), net

    2,809(10,671)Loss on extinguishment of debt/payables

    -(1,514)Derivative warrant liability gain (loss)

    231,543(3,029,897)Other income (expense), net

    234,352(3,042,082)Net loss

    (2,985,770)(4,597,240)Deemed dividend on beneficial conversion feature of Series D Convertible Preferred Stock

    -(1,975,211)Accretion of dividends on Convertible Perpetual Redeemable Preferred Stock

    -(45,684)Net loss applicable to common shareholders

    (6,618,135)Net loss per common share, basic and diluted

    (0.20)Basic and diluted weighted average common shares outstanding



    SOURCE Echo Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    2. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    3. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    4. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    Post Your Comments:
    (Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
    (Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
    (Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
    (Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
    (Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
    (Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
    (Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
    Breaking Medicine News(10 mins):